Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03CDK
|
|||
| Former ID |
DIB006971
|
|||
| Drug Name |
ASP-7147
|
|||
| Indication | Irritable bowel syndrome [ICD-11: DD91.0; ICD-10: K55-K64, K58; ICD-9: 564.1, 787.91] | Phase 2 | [1] | |
| Company |
Astellas Pharma Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastrin-releasing peptide receptor (GRPR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01896583) A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D). U.S. National Institutes of Health. | |||
| REF 2 | Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.